Health-related quality of life outcomes in chronic kidney disease

Soni, Ronak; Weisbord, Steven D.; Unruh, Mark

doi:10.1097/mnh.0b013e328335f939

Cited by 128 publications

(107 citation statements)

References 53 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…QoL may be altered in patients undergoing HD, especially among different races, social relations, cultural diversity and ethnicities (17). Some studies report that it may also be associated with hemoglobin level, socioeconomic status, literacy, dialysis program, gender, comorbidities, depression and previous unsuccessful kidney transplant, as well as clinical manifestations of the disease, side effects, nutritional status and hospitalization (18,19).…”

Section: Discussionmentioning

confidence: 99%

Quality of life and duration of hemodialysis in patients with chronic kidney disease (CKD): a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

Introduction: Quality of life (QoL) of hemodialysis patients is a major evaluative marker currently measured, while treatment time is a clinical determinant associated with impaired QOL. Objective: To evaluate QOL in individuals undergoing hemodialysis (HD) considering treatment time and the presence of comorbidities. Methods: A cross-sectional study conducted in the hemodialysis unit of the Hospital das Clínicas da Universidade Federal de Pernambuco (HC-UFPE). We studied patients with Chronic Kidney Disease (CKD) of both genders over the age of 18 years, at any level of education and undergoing HD for at least 6 months. We evaluated the demographic/socioeconomic and clinical data, followed by application of the quality of life questionnaire (KDQOL-SF). Results: Participants were 47 patients with a mean age of 50.94 ± 13.33 years, 55.3% were male and average treatment time of 57.35 ± 61.46 months. Hypertension (59.6%) was the most frequent underlying disease. According to the responses obtained through the KDQOL-SF, the situation at work and physical limitation scored worse. Sexual function (85.83) and encouragement by the team had the best performance. There were no differences in dimensions of questionnaire and treatment time. Conclusion: The presence of comorbidities and HD duration were not found to be possible factors for changing QoL in this study. However, we suggest that future studies evaluate other factors such as laboratory, emotional and functional data to check for changes in QoL in these patients related to HD duration.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life and duration of hemodialysis in patients with chronic kidney disease (CKD): a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…EPO is mainly produced in the kidney after birth, and its production is severely reduced in patients with chronic kidney disease (CKD) (2) with renal anemia. The cloning of the EPO gene and the production of recombinant human EPO revolutionized the management of patients with CKD, providing an opportunity for safe long-term anemia correction, which improves cognitive function, quality of life, exercise capacity, and cardiac function (3). Nowadays, an increasing number of patients with CKD receive erythropoiesis-stimulating agents (ESAs), and annual US prescription sales for ESAs reached 10 billion dollars in 2006.…”

Section: Introductionmentioning

confidence: 99%

Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice

et al. 2011

View full text Add to dashboard Cite

In chronic kidney disease, fibroblast dysfunction causes renal fibrosis and renal anemia. Renal fibrosis is mediated by the accumulation of myofibroblasts, whereas renal anemia is mediated by the reduced production of fibroblast-derived erythropoietin, a hormone that stimulates erythropoiesis. Despite their importance in chronic kidney disease, the origin and regulatory mechanism of fibroblasts remain unclear. Here, we have demonstrated that the majority of erythropoietin-producing fibroblasts in the healthy kidney originate from myelin protein zero-Cre (P0-Cre) lineage-labeled extrarenal cells, which enter the embryonic kidney at E13.5. In the diseased kidney, P0-Cre lineage-labeled fibroblasts, but not fibroblasts derived from injured tubular epithelial cells through epithelial-mesenchymal transition, transdifferentiated into myofibroblasts and predominantly contributed to fibrosis, with concomitant loss of erythropoietin production. We further demonstrated that attenuated erythropoietin production in transdifferentiated myofibroblasts was restored by the administration of neuroprotective agents, such as dexamethasone and neurotrophins. Moreover, the in vivo administration of tamoxifen, a selective estrogen receptor modulator, restored attenuated erythropoietin production as well as fibrosis in a mouse model of kidney fibrosis. These findings reveal the pathophysiological roles of P0-Cre lineage-labeled fibroblasts in the kidney and clarify the link between renal fibrosis and renal anemia.

show abstract

“…In a study of male veterans, Hedayati et al [21] found that 21% of the sample had experienced a major depressive episode and that the prevalence of depression did not vary according to stage of CKD. Other studies have examined self-reported quality of life within the CKD population and have found that quality of life is significantly impaired in CKD patients when compared to general population norms [22,23] and that the degree of impairment is significantly associated with decline in renal function [24,25]. …”

Section: Introductionmentioning

confidence: 99%

A Preliminary Investigation of Depression and Kidney Functioning in Patients with Chronic Kidney Disease

Cukor¹,

Fruchter²,

Halen³

et al. 2013

Nephron Clin Pract

View full text Add to dashboard Cite

Background: The incidence and prevalence of Chronic Kidney Disease (CKD) is growing rapidly. Understanding the factors associated with declining renal function is of clinical significance. The current study's main goal was to identify variables that could predict decline in glomerular filtration rate (GFR) over time in outpatients with varying stages of CKD. Methods: Seventy CKD patients completed psychological questionnaires and medical variables were extracted from the medical charts. Follow-up GFR was collected 6 months later. CKD patients with elevated depression scores were compared to patients with subclinical depression on medical and psychological variables. Results: Average Beck Depression Inventory (BDI) score was 10.0 ± 7.8, placing the mean below the cut-off for clinical elevation. GFR was significantly different for the two groups (nondepressed, 40.0 ± 11.3 vs. depressed 29.6 ± 8.9; p < 0.05). Similarly, patients with elevated depression scores reported lower quality of life (Short Form 36 Health Survey; p < 0.05) inferior social support (Interpersonal Support Evaluation List; p < 0.05), and worse community integration (Community Integration Questionnaire; p < 0.05). Utilizing a regression, with a model correcting for baseline GFR, the BDI explained 19% of the variance in GFR score (t = -2.0, p < 0.05) for subjects with decreased GFR. Conclusions: Increased levels of preexisting depression were associated with inferior quality of life, social support and kidney functioning. Depression scores explained a significant amount of variance in GFR scores at 6 months even when corrected for baseline variability. Elevated depression scores are prevalent in CKD populations and further research on the impact of depression interventions is warranted.

show abstract

Health-related quality of life outcomes in chronic kidney disease

Cited by 128 publications

References 53 publications

Quality of life and duration of hemodialysis in patients with chronic kidney disease (CKD): a cross-sectional study

Quality of life and duration of hemodialysis in patients with chronic kidney disease (CKD): a cross-sectional study

Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice

A Preliminary Investigation of Depression and Kidney Functioning in Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About